BIOGEN INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent
BIOGEN INC. (BIIB) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent of 2.90% for the 3-month period ending 2010-09-30, per its 10-Q filed 2010-10-26.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAmortization · last filed 2010-10-26
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, amortization, percent for the quarter ending 2010-09-30 was 2.90%, a 222.22% increase year-over-year.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, amortization, percent for the quarter ending 2010-06-30 was 1.50%, a 65.91% decline year-over-year.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, amortization, percent for the quarter ending 2009-09-30 was 0.90%.
- BIOGEN INC. effective income tax rate reconciliation, nondeductible expense, amortization, percent for the quarter ending 2009-06-30 was 4.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Percent 9 month |
|---|---|---|---|
| 2010-09-30 | 2.90% 10-Q · filed 2010-10-26 | 1.80% 10-Q · filed 2010-10-26 | |
| 2010-06-30 | 1.50% 10-Q · filed 2010-07-20 | 1.50% 10-Q · filed 2010-07-20 | |
| 2009-09-30 | 0.90% 10-Q · filed 2010-10-26 | 2.00% 10-Q · filed 2010-10-26 | |
| 2009-06-30 | 4.40% 10-Q · filed 2010-07-20 | 2.80% 10-Q · filed 2010-07-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |